Early Derisking Packages – Secure your drug candidate’s potential
Because every euro, every day, and every data point counts
In early development, each decision can determine whether your drug candidate moves forward or stalls.
For start-ups and biotech innovators, generating the right data at the right time is essential — not only for science, but also for securing funding and investor confidence.
At ERBC, we’ve designed Early Derisking Packages to help you make smart, confident go/no-go decisions before costly regulatory stages.
Our goal: transform uncertainty into insight — faster, smarter, and within your budget.
Why early derisking matters
Early derisking is more than a safety check — it’s a strategic step in preclinical development.
It helps you:
- Identify early risks and prioritize the most promising candidates.
- Generate proof-of-concept data that supports funding rounds or partnerships.
- Avoid costly detours before regulatory submission.
- Accelerate your program, reducing time-to-decision.
With limited resources, early-stage innovators can’t afford to test everything — they need to test what matters most.
What’s included in our Early Derisking Packages
Our modular approach lets you select only what’s relevant to your science, timeline, and budget.
1. Select the Early Core In Vivo Package
- Exploratory studies on mouse or rat (3 animals, male or female).
- Early pharmacodynamic and tolerability data.
- Alliance management for close scientific guidance.
2. Choose your options
- Toxicokinetics
- Histopathology
- Clinical pathology
3. Add complementary modules (optional)
- Scientific due diligence (GENESIS) – optimize your development plan.
- In silico, in vitro, ex vivo screening: QSAR, irritation, efficacy, genetic toxicology, safety pharmacology (hERG), local tolerance.
- Additional investigations: biomarkers, telemetry (respiratory or ECG).
Each module is designed to provide decision-driving data, not just results.
The ERBC advantage
Choosing ERBC means partnering with a one-stop preclinical CRO trusted by innovators across Europe.
- Scientific expertise: our specialists help align your preclinical plan with development goals and regulatory expectations.
- Integrated disciplines: toxicology, pathology, safety pharmacology, imaging, and lab sciences in one platform.
- Operational agility: faster timelines to meet critical milestones.
- Collaborative partnership: transparent communication and project management.
- Competitive pricing: tailored for early-stage biotech and start-ups.
We don’t just execute studies — we help you design the smartest strategy for your drug candidate.
From idea to confident investment
Each discovery deserves the best chance to move forward.
ERBC’s Early Derisking Packages help you build a solid scientific foundation and present investors with credible, data-backed proof of concept.
Download our leaflet to explore the full offer.
Book a call with our scientific team to discuss your program.
